- Home
- SHIP vs CABA Comparison
SHIP vs CABA Comparison
Compare SHIP & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHIP
- CABA
- Stock Information
- Founded
- SHIP 2008
- CABA 2017
- Country
- SHIP Greece
- CABA United States
- Employees
- SHIP N/A
- CABA N/A
- Industry
- SHIP Marine Transportation
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHIP Consumer Discretionary
- CABA Health Care
- Exchange
- SHIP Nasdaq
- CABA Nasdaq
- Market Cap
- SHIP 114.3M
- CABA 118.8M
- IPO Year
- SHIP 2007
- CABA 2019
- Fundamental
- Price
- SHIP $5.54
- CABA $1.21
- Analyst Decision
- SHIP Strong Buy
- CABA Strong Buy
- Analyst Count
- SHIP 1
- CABA 8
- Target Price
- SHIP $11.00
- CABA $21.00
- AVG Volume (30 Days)
- SHIP 81.2K
- CABA 652.6K
- Earning Date
- SHIP 05-19-2025
- CABA 05-19-2025
- Dividend Yield
- SHIP 14.02%
- CABA N/A
- EPS Growth
- SHIP 1658.44
- CABA N/A
- EPS
- SHIP 2.11
- CABA N/A
- Revenue
- SHIP $167,459,000.00
- CABA N/A
- Revenue This Year
- SHIP N/A
- CABA N/A
- Revenue Next Year
- SHIP $21.30
- CABA N/A
- P/E Ratio
- SHIP $2.57
- CABA N/A
- Revenue Growth
- SHIP 51.91
- CABA N/A
- 52 Week Low
- SHIP $4.78
- CABA $0.99
- 52 Week High
- SHIP $13.19
- CABA $13.50
- Technical
- Relative Strength Index (RSI)
- SHIP 43.49
- CABA 44.50
- Support Level
- SHIP $5.37
- CABA $1.23
- Resistance Level
- SHIP $5.85
- CABA $1.41
- Average True Range (ATR)
- SHIP 0.21
- CABA 0.11
- MACD
- SHIP 0.04
- CABA 0.02
- Stochastic Oscillator
- SHIP 52.63
- CABA 39.39
About SHIP Seanergy Maritime Holdings Corp.
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Fellowship, Championship, Partnership, Knightship, Lordship, Gloriuship, Leadership, Geniuship, Premiership, and Squireship, among others.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.